Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 8/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352085 | 0.87 | HPGDS (0.43) | NMT2NMT1TLR2QRFPRSIRT6 | |
| SCHEMBL2159831 | 0.86 | HPGDS (0.42) | NMT2NMT1TLR2QRFPRSIRT6 | |
| SCHEMBL22133062 | 0.86 | HPGDS (0.42) | NMT2NMT1TLR2QRFPRSIRT6 | |
| SCHEMBL15302247 | 0.86 | HPGDS (0.42) | NMT2NMT1TLR2QRFPRSIRT6 | |
| SCHEMBL22674900 | 0.84 | ITGB3 (0.39) | FURINTLR2 | |
| SCHEMBL30435754 | 0.83 | NOD1 (0.46) | FURINNMT2NMT1TLR2SIRT6 | |
| SCHEMBL30830406 | 0.82 | NMT2 (0.44) | FURINNMT2NMT1QRFPRSIRT6 | |
| SCHEMBL29533919 | 0.81 | NPY5R (0.42) | FURINNMT2NMT1QRFPR | |
| SCHEMBL29521437 | 0.81 | EGFR (0.43) | FURINNMT2NMT1 | |
| SCHEMBL30398536 | 0.81 | QRFPR (0.42) | NMT2NMT1TLR2QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | ABAT, SSBP1, PDF | FURIN 2315/4885NMT2 392/4885NMT1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.